IMMUNOGENIC FORMULATION BASED ON OSPC ANTIGENS, INTENDED FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINATION PROCEDURES FOR THE PREPARATION OF THESE ANTIGENS.

摘要

A FOCUS ON THE FORMULATION OF BORRELIA VACCINE, TAKING INTO ACCOUNT THE SEROLOGICAL, GENOTYPIC AND EPIDEMIOLOGICAL INFORMATION BY WHICH THE OSPC PROTEINS OF DIFFERENT BRANCHES OF B. BURGDORFERI ARE GROUPED BETWEEN THEM. OSPC ANTIGENS ARE CHOSEN TO CONSTITUTE A SAMPLE REPRESENTATIVE OF SUCH GROUPS, SO THAT THE RESULTING VACCINE PROVIDES THE GREATEST CROSS-PROTECTION WITH THE LOWEST NUMBER OF ANTIGENS.